Crux Biomedical Inc. (Crus Biomedical) provides clinicians with improved medical treatments for potentially life threatening conditions of the human vascular system. The company was formed by physicians Tom Fogarty and Frank Arko based upon their observations of the clinical limitations of vena cava filters. Crux Biomedical is focussed on development of medical devices in the area of cardiology. Its flagship product is Inferior vena cava filters (IVCF). These filters (IVCF) are designed to prevent an often fatal condition known as pulmonary embolism (PE). The Crux IVC Filter is evaluated at 12 centers of excellence around the United States.
Crux Biomedical, Inc. – Medical Equipment – Deals and Alliances Profile is an essential source for company data and information. The profile examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy as well as highlighting the company’s major recent financial deals.
– Provides key company information for business intelligence needs
– Gives information on the company’s major recent financial deals including Mergers and Acquisitions, asset transactions, PE/VC deals, equity offerings, debt offerings and partnerships.
– Data is supplemented with details on the company’s history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement.